This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Nov 15;362(9396):1678; author reply 1678-9.

doi: 10.1016/S0140-6736(03)14813-1.

The CHARM programme

PMID: 14630459
DOI: 10.1016/S0140-6736(03)14813-1

Comment

The CHARM programme

James Penston. Lancet. 2003.

. 2003 Nov 15;362(9396):1678; author reply 1678-9.

doi: 10.1016/S0140-6736(03)14813-1.

Author

PMID: 14630459
DOI: 10.1016/S0140-6736(03)14813-1

No abstract available

PubMed Disclaimer

Comment on

Candesartan and heart failure: the allure of CHARM.
White HD. White HD. Lancet. 2003 Sep 6;362(9386):754-5. doi: 10.1016/S0140-6736(03)14294-8. Lancet. 2003. PMID: 13678864 No abstract available.
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Pfeffer MA, et al. Lancet. 2003 Sep 6;362(9386):759-66. doi: 10.1016/s0140-6736(03)14282-1. Lancet. 2003. PMID: 13678868 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information